We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NP:NYSENeptune Insurance Holdings Inc. Analysis

Data as of 2026-05-19 - not real-time

$27.22

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

Neptune Insurance is trading at $27.22, just above its 20‑day SMA of $27.17 and comfortably over the 50‑day and 200‑day averages, while the RSI sits at a neutral 51.8 and the MACD has turned bearish with a negative histogram. Volatility remains elevated at 72.6% over the past 30 days and the stock’s beta of 0.85 suggests slightly lower market sensitivity, yet the price sits far above the DCF‑derived fair value of $8.13, implying a significant overvaluation. The forward PE of 42.4 dwarfs the industry average of 16.7, and the price‑to‑book ratio of –17.6 reflects a negative book value per share. Support sits near $24.01 and resistance near $30.73, giving the shares limited upside on the near‑term chart.
On the fundamentals side, revenue grew 28.8% year‑over‑year to $168 M with strong gross (55%) and operating (35%) margins, and Q1 EPS turned positive at $0.09 after a loss‑making prior year. Operating cash flow of $54.0 M supports the current earnings despite the lack of free cash generation. However, the balance sheet is strained with $227 M of debt against only $10.5 M of cash and a negative book value, resulting in zero ROE and ROA. The company announced a $100 M share repurchase alongside a public offering and targets $195 M of revenue for 2026, which has driven analysts to a consensus “buy” and a median price target of $30.5. Overall, the stock combines solid top‑line growth with considerable valuation and balance‑sheet risks. Given the extreme greed sentiment (Fear & Greed Index 88.7), market participants appear overly optimistic, which could exacerbate price corrections.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • Bearish MACD signal
  • Price near resistance with limited upside
  • Significant overvaluation vs DCF

Medium Term

1–3 years
Neutral
Model confidence: 7/10

Key Factors

  • Revenue growth and improving margins
  • Analyst consensus buy and price target above current
  • Share repurchase program supporting demand

Long Term

> 3 years
Positive
Model confidence: 8/10

Key Factors

  • Long‑term flood insurance demand and AI‑driven underwriting
  • Revenue target of $195M for 2026
  • Potential upside if balance‑sheet deleveraging succeeds

Key Metrics & Analysis

Financial Health

Revenue Growth28.80%
Profit Margin20.73%
P/E Ratio42.4
P/B Ratio-17.6
Op. Cash Flow$54.0M
Industry P/E16.7

Technical Analysis

TrendNeutral
RSI51.8
Support$24.01
Resistance$30.73
MA 20$27.17
MA 50$25.09
MA 200$25.17
MACDBearish
VolumeIncreasing
Fear & Greed Index88.73

Valuation

Fair Value$8.13
Target Price$30.25
Upside/Downside11.13%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta0.85
Volatility72.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.